Generate Biomedicines shares are trading higher after HC Wainwright & Co initiated coverage on the stock with a Buy rating and announced a price target of $16.

Benzinga Newsdesk www.benzinga.com Positive 94.8%

Neg 0% Neu 0% Pos 94.8%

Comments

No comments yet. Be the first!